

Lawrence Steinman

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3562413/lawrence-steinman-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

189
papers

21,374
citations

63
h-index

145
g-index

216
ext. papers

23,893
ext. citations

16.2
avg, IF

7.08
L-index

#	Paper	IF	Citations
189	Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. <i>Nature</i> , 1992 , 356, 63-6	50.4	1473
188	Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. <i>Nature Medicine</i> , 2002 , 8, 500-8	50.5	1368
187	A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. <i>Nature Medicine</i> , 2007 , 13, 139-45	50.5	1066
186	The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. <i>Nature</i> , 2002 , 420, 78-84	50.4	949
185	Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. <i>Cell</i> , 1996 , 85, 299-302	56.2	751
184	The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. <i>Science</i> , 2001 , 294, 1731-5	33.3	729
183	Autoantigen microarrays for multiplex characterization of autoantibody responses. <i>Nature Medicine</i> , 2002 , 8, 295-301	50.5	624
182	Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. <i>Nature Reviews Immunology</i> , 2006 , 6, 358-70	36.5	489
181	T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination. <i>Nature</i> , 1985 , 317, 355-8	50.4	475
180	Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. <i>Nature Medicine</i> , 2000 , 6, 1176-82	50.5	446
179	T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. <i>Nature</i> , 1986 , 324, 258-60	50.4	434
178	Elaborate interactions between the immune and nervous systems. <i>Nature Immunology</i> , 2004 , 5, 575-81	19.1	411
177	Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. <i>Nature</i> , 2008 , 451, 1076-81	50.4	406
176	How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. <i>Annals of Neurology</i> , 2006 , 60, 12-21	9.4	404
175	Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. <i>Nature Medicine</i> , 2007 , 13, 935-43	50.5	379
174	Selection for T-cell receptor V beta-D beta-J beta gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis. <i>Nature</i> , 1993 , 362, 68-70	50.4	375
173	Limited heterogeneity of rearranged T-cell receptor V alpha transcripts in brains of multiple sclerosis patients. <i>Nature</i> , 1990 , 345, 344-6	50.4	372

172	Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation. <i>Nature</i> , 1992 , 356, 435-8	50.4	363
171	Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. <i>Nature</i> , 1996 , 379, 343-6	50.4	349
170	Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. <i>Science</i> , 2005 , 310, 850-5	33.3	344
169	1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. <i>Molecular and Cellular Biology</i> , 2011 , 31, 3653-69	4.8	331
168	Inhibitory role for GABA in autoimmune inflammation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 2580-5	11.5	309
167	Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. <i>Nature Medicine</i> , 2007 , 13, 211-7	50.5	266
166	Induction of relapsing paralysis in experimental autoimmune encephalomyelitis by bacterial superantigen. <i>Nature</i> , 1993 , 365, 642-4	50.4	237
165	Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation. <i>Journal of Clinical Investigation</i> , 2007 , 117, 438-47	15.9	234
164	Immunology of relapse and remission in multiple sclerosis. <i>Annual Review of Immunology</i> , 2014 , 32, 257-317	31.7	217
163	Design of effective immunotherapy for human autoimmunity. <i>Nature</i> , 2005 , 435, 612-9	50.4	217
162	Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. <i>Annual Review of Neuroscience</i> , 2002 , 25, 491-505	17	199
161	Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. <i>Trends in Immunology</i> , 2005 , 26, 565-71	14.4	190
160	B-lymphocyte-mediated delayed cognitive impairment following stroke. <i>Journal of Neuroscience</i> , 2015 , 35, 2133-45	6.6	188
159	Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 4777-82	11.5	182
158	Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. <i>Journal of Experimental Medicine</i> , 2006 , 203, 401-12	16.6	174
157	Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2. <i>Science Translational Medicine</i> , 2015 , 7, 294ra105	17.5	167
156	Single-cell mass cytometry reveals distinct populations of brain myeloid cells in mouse neuroinflammation and neurodegeneration models. <i>Nature Neuroscience</i> , 2018 , 21, 541-551	25.5	164
155	An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide. <i>Nature Immunology</i> , 2001 , 2, 216-22	19.1	161

154	A rush to judgment on Th17. <i>Journal of Experimental Medicine</i> , 2008 , 205, 1517-22	16.6	153
153	A molecular trio in relapse and remission in multiple sclerosis. <i>Nature Reviews Immunology</i> , 2009 , 9, 440-36.5	36.5	150
152	Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. <i>Annals of Neurology</i> , 2008 , 63, 611-20	9.4	143
151	HDL-bound sphingosine-1-phosphate restrains lymphopoiesis and neuroinflammation. <i>Nature</i> , 2015 , 523, 342-6	50.4	142
150	Peroxisome proliferator-activated receptor (PPAR) and γ regulate IFN γ and IL-17A production by human T cells in a sex-specific way. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 9505-10	11.5	125
149	Involvement of both Allergic and Autoimmune mechanisms in EAE, MS and other autoimmune diseases. <i>Trends in Immunology</i> , 2003 , 24, 479-84	14.4	121
148	Immune therapy for autoimmune diseases. <i>Science</i> , 2004 , 305, 212-6	33.3	117
147	Systemic augmentation of alphaB-crystallin provides therapeutic benefit twelve hours post-stroke onset via immune modulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 13287-92	11.5	109
146	Defective sphingosine 1-phosphate receptor 1 (S1P1) phosphorylation exacerbates TH17-mediated autoimmune neuroinflammation. <i>Nature Immunology</i> , 2013 , 14, 1166-72	19.1	108
145	Mixed results with modulation of TH-17 cells in human autoimmune diseases. <i>Nature Immunology</i> , 2010 , 11, 41-4	19.1	103
144	Nanosensor detection of an immunoregulatory tryptophan influx/kynurenine efflux cycle. <i>PLoS Biology</i> , 2007 , 5, e257	9.7	99
143	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. <i>Lancet Neurology, The</i> , 2019 , 18, 1021-1033	24.1	98
142	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. <i>Lancet Neurology, The</i> , 2019 , 18, 1009-1020	24.1	96
141	Transcriptional analysis of targets in multiple sclerosis. <i>Nature Reviews Immunology</i> , 2003 , 3, 483-92	36.5	96
140	Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants. <i>Journal of Autoimmunity</i> , 2014 , 50, 1-11	15.5	93
139	Natalizumab: bench to bedside and beyond. <i>JAMA Neurology</i> , 2013 , 70, 172-82	17.2	91
138	Differential activation of human autoreactive T cell clones by altered peptide ligands derived from myelin basic protein peptide (87-99). <i>European Journal of Immunology</i> , 1996 , 26, 2624-34	6.1	91
137	Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. <i>Neurology</i> , 2016 , 86, 382-90	6.5	90

136	Alphab-crystallin is a target for adaptive immune responses and a trigger of innate responses in preactive multiple sclerosis lesions. <i>Journal of Neuropathology and Experimental Neurology</i> , 2010 , 69, 694-703	3.1	89
135	Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. <i>Journal of Clinical Investigation</i> , 2006 , 116, 1037-44	15.9	89
134	Nuanced roles of cytokines in three major human brain disorders. <i>Journal of Clinical Investigation</i> , 2008 , 118, 3557-63	15.9	88
133	Isolation of a complementary DNA clone encoding an autoantigen recognized by an anti-neuronal cell antibody from a patient with paraneoplastic cerebellar degeneration. <i>Annals of Neurology</i> , 1990 , 28, 692-8	9.4	83
132	Epstein-Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies. <i>Trends in Molecular Medicine</i> , 2020 , 26, 296-310	11.5	82
131	Some misconceptions about understanding autoimmunity through experiments with knockouts. <i>Journal of Experimental Medicine</i> , 1997 , 185, 2039-41	16.6	81
130	IL-7 promotes T(H)1 development and serum IL-7 predicts clinical response to interferon- β in multiple sclerosis. <i>Science Translational Medicine</i> , 2011 , 3, 93ra68	17.5	77
129	Therapeutic decisions in multiple sclerosis: moving beyond efficacy. <i>JAMA Neurology</i> , 2013 , 70, 1315-24	17.2	67
128	Therapeutic effects of systemic administration of chaperone B-crystallin associated with binding proinflammatory plasma proteins. <i>Journal of Biological Chemistry</i> , 2012 , 287, 9708-9721	5.4	67
127	CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, 927-936	5.5	63
126	Optimization of current and future therapy for autoimmune diseases. <i>Nature Medicine</i> , 2012 , 18, 59-65	50.5	61
125	Autoimmune disease. <i>Scientific American</i> , 1993 , 269, 106-14	0.5	60
124	Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 8463-8470	11.5	59
123	Statins as potential therapeutic agents in neuroinflammatory disorders. <i>Current Opinion in Neurology</i> , 2003 , 16, 393-401	7.1	59
122	Reduced development of COVID-19 in children reveals molecular checkpoints gating pathogenesis illuminating potential therapeutics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 24620-24626	11.5	59
121	Statins in the treatment of central nervous system autoimmune disease. <i>Journal of Neuroimmunology</i> , 2006 , 178, 140-8	3.5	55
120	Prolactin: a versatile regulator of inflammation and autoimmune pathology. <i>Autoimmunity Reviews</i> , 2015 , 14, 223-30	13.6	54
119	Idiotypic immunization induces immunity to mutated p53 and tumor rejection. <i>Nature Medicine</i> , 1998 , 4, 710-2	50.5	52

118	A neuropeptide in immune-mediated inflammation, Y?. <i>Trends in Immunology</i> , 2006 , 27, 164-7	14.4	52
117	Identification of naturally occurring fatty acids of the myelin sheath that resolve neuroinflammation. <i>Science Translational Medicine</i> , 2012 , 4, 137ra73	17.5	51
116	Protein and Peptide Array Analysis of Autoimmune Disease. <i>BioTechniques</i> , 2002 , 33, S66-S69	2.5	51
115	Clonally Expanded B Cells in Multiple Sclerosis Bind EBV EBNA1 and GlialCAM.. <i>Nature</i> , 2022 ,	50.4	51
114	IFN- β treatment requires B cells for efficacy in neuroautoimmunity. <i>Journal of Immunology</i> , 2015 , 194, 2110-6	5.3	50
113	Non-progressing cancer patients have persistent B cell responses expressing shared antibody paratopes that target public tumor antigens. <i>Clinical Immunology</i> , 2018 , 187, 37-45	9	49
112	The discovery of natalizumab, a potent therapeutic for multiple sclerosis. <i>Journal of Cell Biology</i> , 2012 , 199, 413-6	7.3	46
111	Optic neuritis, a new variant of experimental encephalomyelitis, a durable model for all seasons, now in its seventieth year. <i>Journal of Experimental Medicine</i> , 2003 , 197, 1065-71	16.6	46
110	An interferon- β resistant and NLRP3 inflammasome-independent subtype of EAE with neuronal damage. <i>Nature Neuroscience</i> , 2016 , 19, 1599-1609	25.5	44
109	Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 1600-5	11.5	44
108	Tolerance checkpoint bypass permits emergence of pathogenic T cells to neuromyelitis optica autoantigen aquaporin-4. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 14781-14786	11.5	44
107	Molecular signature of Epstein-Barr virus infection in MS brain lesions. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018 , 5, e466	9.1	40
106	Neoplastic and reactive human astrocytes express interleukin-8 gene. <i>Neurosurgical Review</i> , 1992 , 15, 203-7	3.9	40
105	Hyaluronan synthesis is necessary for autoreactive T-cell trafficking, activation, and Th1 polarization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 1339-44	11.5	39
104	Multiplexed autoantigen microarrays identify HLA as a key driver of anti-desmoglein and -non-desmoglein reactivities in pemphigus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 1859-64	11.5	38
103	The interdependent, overlapping, and differential roles of type I and II IFNs in the pathogenesis of experimental autoimmune encephalomyelitis. <i>Journal of Immunology</i> , 2013 , 191, 2967-77	5.3	38
102	Inflammatory cytokines at the summits of pathological signal cascades in brain diseases. <i>Science Signaling</i> , 2013 , 6, pe3	8.8	37
101	mir-181a-1/b-1 Modulates Tolerance through Opposing Activities in Selection and Peripheral T Cell Function. <i>Journal of Immunology</i> , 2015 , 195, 1470-9	5.3	35

100	Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides. <i>International Reviews of Immunology</i> , 2005 , 24, 415-46	4.6	35
99	Interleukin 17F level and interferon γ response in patients with multiple sclerosis. <i>JAMA Neurology</i> , 2013 , 70, 1017-21	17.2	31
98	Millennium Award. Proteomics for the development of DNA tolerizing vaccines to treat autoimmune disease. <i>Clinical Immunology</i> , 2002 , 103, 7-12	9	31
97	Prospects for specific immunotherapy in myasthenia gravis. <i>FASEB Journal</i> , 1990 , 4, 2726-31	0.9	31
96	Regulator of oligodendrocyte maturation, miR-219, a potential biomarker for MS. <i>Journal of Neuroinflammation</i> , 2017 , 14, 235	10.1	28
95	High-throughput methods for measuring autoantibodies in systemic lupus erythematosus and other autoimmune diseases. <i>Autoimmunity</i> , 2004 , 37, 269-72	3	28
94	Drug Insight: using statins to treat neuroinflammatory disease. <i>Nature Clinical Practice Neurology</i> , 2005 , 1, 106-12		27
93	Iron-sulfur glutaredoxin 2 protects oligodendrocytes against damage induced by nitric oxide release from activated microglia. <i>Glia</i> , 2017 , 65, 1521-1534	9	26
92	Phosphorylation of B-crystallin supports reactive astrogliosis in demyelination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, E1745-E1754	11.5	25
91	Part II. high-dose methotrexate with leucovorin rescue for severe COVID-19: An immune stabilization strategy for SARS-CoV-2 induced PANIC attack. <i>Journal of the Neurological Sciences</i> , 2020 , 415, 116935	3.2	24
90	Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1255-1262	5	24
89	Myelin basic protein peptide specificity and T-cell receptor gene usage of HPRT mutant T-cell clones in patients with multiple sclerosis. <i>Annals of Neurology</i> , 1994 , 36, 734-40	9.4	24
88	Antigen-specific tolerance to self-antigens in protein replacement therapy, gene therapy and autoimmunity. <i>Current Opinion in Immunology</i> , 2019 , 61, 46-53	7.8	23
87	Tissue Transglutaminase contributes to experimental multiple sclerosis pathogenesis and clinical outcome by promoting macrophage migration. <i>Brain, Behavior, and Immunity</i> , 2015 , 50, 141-154	16.6	23
86	Clinical optimization of antigen specific modulation of type 1 diabetes with the plasmid DNA platform. <i>Clinical Immunology</i> , 2013 , 149, 297-306	9	22
85	Modulation of postoperative cognitive decline via blockade of inflammatory cytokines outside the brain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 20595-6	11.5	21
84	An analysis of T-cell-receptor variable-region genes in tumor-infiltrating lymphocytes within malignant tumors. <i>International Journal of Cancer</i> , 1991 , 49, 545-50	7.5	21
83	Myoblast transfer in DMD: problems in the interpretation of efficiency. <i>Muscle and Nerve</i> , 1992 , 15, 1209-10	3.10	21

82	Multiple sclerosis and its animal models: the role of the major histocompatibility complex and the T cell receptor repertoire. <i>Seminars in Immunopathology</i> , 1992 , 14, 79-93		20
81	Beginning of the end of two-stage theory purporting that inflammation then degeneration explains pathogenesis of progressive multiple sclerosis. <i>Current Opinion in Neurology</i> , 2016 , 29, 340-4	7.1	19
80	Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity. <i>Journal of Neuroinflammation</i> , 2014 , 11, 29	10.1	19
79	Shifting therapeutic attention in MS to osteopontin, type 1 and type 2 IFN. <i>European Journal of Immunology</i> , 2009 , 39, 2358-60	6.1	19
78	Antigen-specific therapy of multiple sclerosis: the long-sought magic bullet. <i>Neurotherapeutics</i> , 2007 , 4, 661-5	6.4	19
77	No quiet surrender: molecular guardians in multiple sclerosis brain. <i>Journal of Clinical Investigation</i> , 2015 , 125, 1371-8	15.9	18
76	Amelioration of ongoing experimental autoimmune encephalomyelitis with fluoxetine. <i>Journal of Neuroimmunology</i> , 2017 , 313, 77-81	3.5	18
75	State of the art. Four easy pieces: interconnections between tissue injury, intermediary metabolism, autoimmunity, and chronic degeneration. <i>Proceedings of the American Thoracic Society</i> , 2006 , 3, 484-6		18
74	Amyloid fibrils activate B-1a lymphocytes to ameliorate inflammatory brain disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 15016-23	11.5	17
73	Nogo in multiple sclerosis: growing roles of a growth inhibitor. <i>Journal of the Neurological Sciences</i> , 2006 , 245, 201-10	3.2	17
72	Time correlation between mononucleosis and initial symptoms of MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017 , 4, e308	9.1	16
71	The re-emergence of antigen-specific tolerance as a potential therapy for MS. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1223-38	5	16
70	Identification of a common immune regulatory pathway induced by small heat shock proteins, amyloid fibrils, and nicotine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, 7081-7086	11.5	16
69	From defining antigens to new therapies in multiple sclerosis: honoring the contributions of Ruth Arnon and Michael Sela. <i>Journal of Autoimmunity</i> , 2014 , 54, 1-7	15.5	16
68	The gray aspects of white matter disease in multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 8083-4	11.5	16
67	Part I. SARS-CoV-2 triggered PANIC attack in severe COVID-19. <i>Journal of the Neurological Sciences</i> , 2020 , 415, 116936	3.2	16
66	Thymic epithelium determines a spontaneous chronic neuritis in Icam1(tm1Jcgr)NOD mice. <i>Journal of Immunology</i> , 2014 , 193, 2678-90	5.3	15
65	Adrenocorticotrophic hormone methylprednisolone added to interferon β in patients with multiple sclerosis experiencing breakthrough disease: a randomized, rater-blinded trial. <i>Therapeutic Advances in Neurological Disorders</i> , 2017 , 10, 3-17	6.6	14

64	DNA threads released by activated CD4 T lymphocytes provide autocrine costimulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 8985-8994	11.5	14
63	The gender gap in multiple sclerosis: intersection of science and society. <i>JAMA Neurology</i> , 2013 , 70, 634-57.2	5.7	14
62	The neuropathology of propionic acidemia. <i>Developmental Medicine and Child Neurology</i> , 1983 , 25, 87-94	3.3	14
61	HTLV-I sequences are not detected in peripheral blood genomic DNA or in brain cDNA of multiple sclerosis patients. <i>Annals of Neurology</i> , 1990 , 28, 574-7	9.4	14
60	Engineered DNA plasmid reduces immunity to dystrophin while improving muscle force in a model of gene therapy of Duchenne dystrophy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E9182-E9191	11.5	14
59	Uncovering cryptic glycan markers in multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE). <i>Drug Development Research</i> , 2014 , 75, 172-88	5.1	13
58	Epstein-Barr virus and multiple sclerosis.. <i>Science</i> , 2022 , 375, 264-265	33.3	13
57	New targets and therapeutics for neuroprotection, remyelination and repair in multiple sclerosis. <i>Expert Opinion on Investigational Drugs</i> , 2020 , 29, 443-459	5.9	13
56	Janus faces of amyloid proteins in neuroinflammation. <i>Journal of Clinical Immunology</i> , 2014 , 34 Suppl 1, S61-3	5.7	12
55	Conflicting consequences of immunity to cancer versus autoimmunity to neurons: insights from paraneoplastic disease. <i>European Journal of Immunology</i> , 2014 , 44, 3201-5	6.1	12
54	CRYAB modulates the activation of CD4+ T cells from relapsing-remitting multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1867-77	5	12
53	Lessons learned at the intersection of immunology and neuroscience. <i>Journal of Clinical Investigation</i> , 2012 , 122, 1146-8	15.9	12
52	Autoantibodies against central nervous system antigens in a subset of B cell-dominant multiple sclerosis patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 21512-21518	11.5	12
51	Mechanistic insights into influenza vaccine-associated narcolepsy. <i>Human Vaccines and Immunotherapeutics</i> , 2016 , 12, 3196-3201	4.4	12
50	Mechanisms of action of therapeutic amyloidogenic hexapeptides in amelioration of inflammatory brain disease. <i>Journal of Experimental Medicine</i> , 2014 , 211, 1847-56	16.6	11
49	Induction of New Autoimmune Diseases After Alemtuzumab Therapy for Multiple Sclerosis: Learning From Adversity. <i>JAMA Neurology</i> , 2017 , 74, 907-908	17.2	10
48	Weighing in on autoimmune disease: Club-and-spoke cell traffic in autoimmunity. <i>Nature Medicine</i> , 2013 , 19, 139-41	50.5	10
47	New targets for treatment of multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2008 , 274, 1-4	3.2	9

46	EAE: a model for immune intervention with synthetic peptides. <i>International Reviews of Immunology</i> , 1992 , 9, 223-30	4.6	9
45	COVID-19 therapeutics: Challenges and directions for the future.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022 , 119, e2119893119	11.5	9
44	Development of therapies for autoimmune disease at Stanford: a tale of multiple shots and one goal. <i>Immunologic Research</i> , 2014 , 58, 307-14	4.3	8
43	T cell recognition in experimental autoimmune encephalomyelitis: prospects for immune intervention with synthetic peptides. <i>International Reviews of Immunology</i> , 1990 , 6, 37-47	4.6	8
42	Mitigating alemtuzumab-associated autoimmunity in MS: A "whack-a-mole" B-cell depletion strategy. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	8
41	Combining statins with interferon β in multiple sclerosis: think twice, it might not be all right. <i>Lancet Neurology</i> , 2011 , 10, 672-3	24.1	7
40	Anti-Insulin Immune Responses Are Detectable in Dogs with Spontaneous Diabetes. <i>PLoS ONE</i> , 2016 , 11, e0152397	3.7	7
39	Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	7
38	Treatment with anti-Fc γ R1 antibody exacerbates EAE and T-cell immunity against myelin. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017 , 4, e342	9.1	6
37	CEACAM1 mediates B cell aggregation in central nervous system autoimmunity. <i>Scientific Reports</i> , 2016 , 6, 29847	4.9	6
36	Gene expression analysis of histamine receptors in peripheral blood mononuclear cells from individuals with clinically-isolated syndrome and different stages of multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2014 , 277, 186-8	3.5	6
35	Anaphylaxis to a self-peptide in the absence of mast cells or histamine. <i>Laboratory Investigation</i> , 2009 , 89, 398-405	5.9	6
34	Superantigens in demyelinating disease. <i>Seminars in Immunopathology</i> , 1996 , 18, 51-6		6
33	Narcolepsy and influenza vaccination-induced autoimmunity. <i>Annals of Translational Medicine</i> , 2017 , 5, 25	3.2	6
32	Identification of Candidate Tolerogenic CD8(+) T Cell Epitopes for Therapy of Type 1 Diabetes in the NOD Mouse Model. <i>Journal of Diabetes Research</i> , 2016 , 2016, 9083103	3.9	6
31	T Cell-Transfer Experimental Autoimmune Encephalomyelitis: Pillar of Multiple Sclerosis and Autoimmunity. <i>Journal of Immunology</i> , 2017 , 198, 3381-3383	5.3	5
30	Self-Assembling Peptides Form Immune Suppressive Amyloid Fibrils Effective in Autoimmune Encephalomyelitis. <i>Current Topics in Behavioral Neurosciences</i> , 2015 , 26, 221-32	3.4	5
29	Nonclassical monocytes: are they the next therapeutic targets in multiple sclerosis?. <i>Immunology and Cell Biology</i> , 2018 , 96, 125-127	5	5

28	CD4 cell response to interval therapy with natalizumab. <i>Annals of Clinical and Translational Neurology</i> , 2015 , 2, 570-4	5.3	5
27	Piet Mondrian@ trees and the evolution in understanding multiple sclerosis, Charcot Prize Lecture 2011. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 5-14	5	5
26	Controlling autoimmunity in sporadic inclusion-body myositis. <i>Neurology</i> , 2006 , 66, S56-8	6.5	5
25	Calibration of cell-intrinsic interleukin-2 response thresholds guides design of a regulatory T cell biased agonist. <i>ELife</i> , 2021 , 10,	8.9	4
24	Small Heat Shock Proteins, Amyloid Fibrils, and Nicotine Stimulate a Common Immune Suppressive Pathway with Implications for Future Therapies. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2019 , 9,	5.4	4
23	A sugar-coated strategy to treat a rare neurologic disease provides a blueprint for a decoy glycan therapeutic and a potential vaccine for CoViD-19: An Editorial Highlight for "Selective inhibition of anti-MAG IgM autoantibody binding to myelin by an antigen specific glycopolymer" on page 486. <i>Journal of Neurochemists</i> , 2020 , 151, 115-117	6	3
22	Genetic background modulates outcome of therapeutic amyloid peptides in treatment of neuroinflammation. <i>Journal of Neuroimmunology</i> , 2016 , 298, 42-50	3.5	3
21	Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4. <i>Journal of Visualized Experiments</i> , 2017 ,	1.6	3
20	Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 51, 102844	4	3
19	Axonal and Myelin Neuroprotection by the Peptoid BN201 in Brain Inflammation. <i>Neurotherapeutics</i> , 2019 , 16, 808-827	6.4	3
18	A century of pavlovian experiments forming a circuit from the elucidation of neural reflexes to pharmaceuticals and electroceuticals to treat diseases. <i>Brain, Behavior, and Immunity</i> , 2015 , 44, 17-8	16.6	2
17	Targeting molecules involved in immune cell trafficking to the central nervous system for therapy in multiple sclerosis. <i>Clinical and Experimental Neuroimmunology</i> , 2017 , 8, 183-191	0.4	2
16	Role reversal: infiltrating T cells protect the brain. <i>Journal of Clinical Investigation</i> , 2015 , 125, 493-4	15.9	2
15	Going viral and the fatal vulnerability of neurons from immunity, not from infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 16982-3	11.5	2
14	A Journey in Science: The Privilege of Exploring the Brain and the Immune System. <i>Molecular Medicine</i> , 2016 , 22,	6.2	2
13	Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials. <i>European Journal of Neurology</i> , 2021 , 28, 3722-3730	6	2
12	Parsing Physiological Functions of Erythropoietin One Domain at a Time. <i>Neurotherapeutics</i> , 2015 , 12, 848-9	6.4	1
11	Response to comment on "Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2". <i>Science Translational Medicine</i> , 2015 , 7, 314lr2	17.5	1

10	An amyloidogenic hexapeptide derived from amylin attenuates inflammation and acute lung injury in murine sepsis. <i>PLoS ONE</i> , 2018 , 13, e0199206	3.7	1
9	The emergence of neuroepidemiology, neurovirology and neuroimmunology: the legacies of John F. Kurtzke and Richard Plick. Johnson. <i>Journal of Neurology</i> , 2017 , 264, 817-828	5.5	1
8	Pathogenic T helper 1 cells reach the brain before T helper 17 cells, and T regulatory cells suppress them albeit incompletely. <i>Acta Neuropathologica</i> , 2013 , 126, 517-8	14.3	1
7	Blocking immune intrusion into the brain suppresses epilepsy in Rasmussen's encephalitis model. <i>Journal of Clinical Investigation</i> , 2018 , 128, 1724-1726	15.9	1
6	Nostalgia: the similarities between immunological and neurological memory. <i>Immunological Reviews</i> , 2012 , 248, 5-9	11.3	
5	Evaluating human T cell receptor gene expression by PCR. <i>Current Protocols in Immunology</i> , 2001 , Chapter 10, Unit 10.26	4	
4	Type II HMG-CoA Reductase Inhibitors (Statins) Provide Acute-Graft-Versus-Host Disease Protection by Th-2 Cytokine Induction While Sparing Graft-Versus-Leukemia Activity.. <i>Blood</i> , 2006 , 108, 189-189	2.2	
3	Autoimmune Diseases: The Role for Vaccines 2020 , 375-381		
2	Capturing pathogenic immune cells before they home to brain. <i>Med</i> , 2021 , 2, 214-216	31.7	
1	Mobilization of innate and adaptive antitumor immune responses by the RNP-targeting antibody ATRC-101.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022 , 119, e2123483119	11.5	